WO2026067515 - COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/067515
Publication Date
02.04.2026
International Application No.
PCT/CN2025/123903
International Filing Date
25.09.2025
Title **
[English]
COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
[French]
COMPOSÉ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
一种化合物及其制备方法和用途
Applicants **
CHENGDU MFS PHARMA. CO., LTD.
Inventors
CHEN, Guangwu
LIU, Jin
ZHANG, Wensheng
ZHANG, Hancheng
GUO, Lina
Priority Data
202411363077.5
27.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2696 | |
| EPO | Filing, Examination, Granting | 15506 | |
| Japan | Filing, Examination, Granting | 2122 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 5640 |
Total:
28,035
Contact Us
Abstract[English]
The present invention belongs to the technical field of medicine. Provided are a compound, and a preparation method therefor and the use thereof. The compound has a structure as shown in formula I. The compound of the present invention not only has efficient sedative, hypnotic and/or anesthetic effects, and the ability to control status epilepticus, but also exhibits an analgesic effect, and can reduce or avoid the use of opioid analgesics such as fentanyl, alfentanil, sufentanil or remifentanil in clinical application, thereby reducing the occurrence of adverse reactions such as circulatory depression, respiratory depression, urinary retention and pruritus caused by opioid analgesics.[French]
La présente invention se rapporte au domaine technique de la médecine. L'invention concerne un composé, son procédé de préparation et son utilisation. Le composé a une structure telle que représentée dans la formule I. Le composé selon la présente invention présente non seulement des effets sédatifs, hypnotiques et/ou anesthésiques efficaces, et la capacité de réguler l'état épileptique, mais présente également un effet analgésique, et peut réduire ou éviter l'utilisation d'analgésiques opioïdes tels que le fentanyl, l'alfentanil, le sufentanil ou le remifentanil dans une application clinique, ce qui permet de réduire l'apparition de réactions indésirables telles que la dépression circulatoire, la dépression respiratoire, la rétention urinaire et le prurit provoqué par des analgésiques opioïdes.[Chinese]
本发明提供了一种化合物及其制备方法和用途，属于医药技术领域。该化合物的结构如式I所示。本发明化合物不仅具有高效的镇静、催眠和/或麻醉作用，能够控制癫痫持续状态，同时还具有镇痛作用，临床应用时可以减少或不用如芬太尼、阿芬太尼、舒芬太尼或瑞芬太尼等阿片类镇痛药物，从而减少阿片类镇痛药物循环抑制、呼吸抑制、尿潴留、皮肤瘙痒等不良反应的发生。